Alvogen builds on Asian Dream with $187m acquisition
US-based generics company Alvogen has shelled out $187m for its third major acquisition in Asia in two years, scooping up South Korea's Dream Pharma.
US-based generics company Alvogen has shelled out $187m for its third major acquisition in Asia in two years, scooping up South Korea's Dream Pharma.